Early responses to chemotherapy detected by pulse cytophotometry. by Smets, L. A. et al.
Br. J. Cancer (1976) 34, 153
EARLY RESPONSES TO CHEMOTHERAPY DETECTED BY PULSE
CYTOPHOTOMETRY
L. A. SMEIETS*, E. MIULDERt, F. C. de WA'AALt, F. J. CLETON* and J. BLOK*.
Fromn *The Antoni vant Leeuwenhoek Laboratory, The Netherlands Cancer Institute, Sarphatistraat 108,
Amsterdam anid tThe Departmenit of Paediatrics, Acadern ic Hospital, Free University, Amsterdam,
The Netherlands
Received 8 'March 1976 Accepted 20 April 1976
Summary.-DNA/cell distributions were recorded by automated cytofluorometry
( = pulse cytophotometry) in bone-marrow aspirates of leukaemia and lympho-
sarcoma patients subjected to chemotherapy. In most cases, early perturbations
in DNA/cell histographs were observed, characteristically reflecting the known mode
of action of the drugs. These changes in general preceded the clinical observation
of drug response.
In a series of23 measurements in 19 patients, a positive correlation between early
cytophotometric changes and clinical effects of chemotherapy was observed in 17
patients. Five patients were negative for both cytophotometric and clinical re-
actions and one patient was probably false-positive. The validity of the assay for
early detection of drug resistance in acute leukaemia and related diseases is
discussed.
PULSE CYTOPHOTOMETERS can measure
the DNA content of single cells in suspen-
sion stained by specific, fluorescent dyes
(Crissman, Mtillaney and Steiiikamp, 1975;
Gohde, 1973). DNA/cell distributions of
high statistical reliability can be obtained
within 2 h following sampling of cells.
The main advantage of pulse cytophoto-
metry over radioautography resides in the
speed and simplicity with which the
information isobtained. Moreover, DNA/
cell distributions yield direct information
regarding the frequency of cells outside
the S compartment even when the
radioautographic technique is rendered
blind by drugs which interfere with DNA
synthesis. The technique has been used
to coirrelate proliferative activity and
remission expectation in adult AML
(Hillen, 1aanen and Wessels, 1975) and to
(letect circulating tumour cells in the
peripheral blood of lymphoma patients
(Cleton et al., 1975).
Pulse cytophotometry might find clini-
cal application in monitoring individual
cytokinetic responses during chemotherapy.
The information thus obtained could be
of prognostic value for the clinical
effectiveness of the drug used and eventu-
ally result in the timely adjustment of the
chemotherapeuticstrategy (Haanen, 1975).
In the present study, we investigated
firstly, whether DNA/cell distributions
from bone-marrow aspirates, recorded in
the early phase of cytostatic treatment,
displayed perturbations representative of
the known action of a variety of drugs.
Secondly, in a number of cases the
presence or absence of characteristic
changes was correlated with the clinical
evaluation of drug effectiveness.
MATERIALS AND METHODS
Patients and cell sampling.-Bone-marrow
aspirates were obtained from 30 patients,
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mainly children, awaiting chemotherapy in
various hospitals in Amsterdam. Most
patients were in relapse of their disease and
had not been subjected to chemotherapy for
at least one week. In general, diagnosis,
treatment schedule and clinical response to
treatment were not known to those per-
forming the cytophotometric assay and the
comparison of laboratory and clinical results
was made a posteriori. Since the treatment
schedules were not always identical in the
various hospitals and for the individual
patients, the details were not recorded unless
relevant to the purpose of this study.
Prednisone and vincristine (40 mg/M2
and 2 mg/M2 respectively), cytosine arabino-
side (100 mg/m2/day) and adriamycin (30
mg/M2) were given by i.v. injections. L-
asparaginase was given by i.v. drip of 4 h
daily and MOPP was infused for 24 h before
marrow aspiration. Melphalan was taken
per os in a dosage of 18 mg/day. All tumour
samples taken before treatment were in-
vestigated to confirm that the samples
contained 80% or more tumour cells.
Samples of approx. 1 ml were suspended
in 3 ml of phosphate-buffered saline and
defibrinated by shaking with glass beads
for 10 min and transported to the laboratory
on ice. The suspensions were freed from
granulocytes, erythrocytes and dead cells by
Ficoll-Isopaque gradient centrifugation (de
Vries, van Benthem and Rumke, 1973).
The cells accumulated at the interphase
were fixed in 70% ethanol and stored at
4°C. From about half the samples, radio-
autographs were prepared by incubating
aliquots of the defibrinated suspensions in
3H-thymidine for 60min.
Analysis by pulse cytophotometry.-About
5 x 106 fixed cells were successively in-
cubated in RNase (Sigma, 5x crystallized;
500 parts/106 for 30 min at 37°C) and pepsin
(Merck, 5u/ml for 15 min in 0.2% HCI at
37°C). The cells were then washed twice in
Tris-HCl buffer, pH 7-2, and resuspended in
the staining solution which contained 10
parts/106 ethidium bromide and 2 parts/106
of the stain Hoechst 33258 (Berkhan, 1975).
DNA/cell fluorescence was measured in
the PHYWE, ICP 11 pulse cytophotometer
at a rate of 400 cells/s. For each histograph
at least 50,000 cells were counted. Per-
centages ofcells with DNA values correspond-
ing with G1, S and G2 or M phase were
calculated by planimetry. The calculation
of S-phase cells was controlled via radio-
autography in about half the untreated cases
and found to give identical results. During
chemotherapy, particularly with cytosine ara-
binoside, large variations were sometimes
found between fractions of cells with S-phase
DNA content and of cells actively incorpora-
ting 3H-thymidine. Changes in the DNA/
cell histographs were scored as positive if at
least a two-fold change in the frequency of
cells in either phase of the cell cycle was
observed in 2 separate measurements on a
sample of fixed cells. Variations between
duplicate samples obtained from some un-
treated patients all fell within these limits.
RESULTS
Prednisone and vincristine
The effect of treatment with predni-
sone and vincristine was studied in 7
patients with ALL, 2 patients with
leukaemic transformed lymphosarcoma,
1 patient with neuroblastoma infiltrated
into the bone-marrow and 1 patient with
monocytic leukaemia. Samples were in-
vestigated at several times after the start
of treatment but consistent changes were
first observed after 24 h. All except 1
patient reacted by depression of the
number of S-phase cells, ranging from a
2-fold to a 10-fold reduction. The re-
sponse was most evident in patients
showing a high number of S-phase cells
at the start of therapy (Fig. 1). A
decrease in the fraction of S-phase cells
reflects the known inhibition by cortico-
steroids of the transition from G1 to
S phase (Mauer, 1975) and corroborates
the results of other workers (Hillen et al.,
1975).
Accumulation of cells with tetraploid
DNA content, due to the mitostatic
effect of vincristine, was observed only in
the adult patients and in a case of child-
hood ALL in remission. In the latter
patient, mainly erythroblasts blocked in
mitosis were observed in the smears.
Apparently, either tumour blasts in child-
hood leukaemia were lysed by the cortico-
steroids before or during accumulation in
metaphase, or these cells had becomePULSE CYTOPHIOTOMETRY AIDS CHEMOTHERAPY
Cels per cha l-u 4;-2
- A
0 20
I
- B %S=3.2
L
0 .20
FIG. 1.-DNA/cell distribution of lymphosarcoma cells before (curve A) and 24 h after chemotherapy (curve B) with prednisone and vincristine (Table, P.W.). The shaded area represents the ten-fold
electronic amplification of the information stored in the channels below (dark area). Channel
33 = DNA content of G1 cells; channel 65 = same of G2- and M-phase cells; channels 40-60 =
range ofS-phase cells. Note heavy depression ofcells in S and G2 phase.
particularly sensitive to the preparative
techniques and were selectively lost in the
preparation (see discussion).
Cytosine arabinoside
Effects of cytosine arabinoside (Ara-C)
were investigated in 4 children and 3
adults in relapse of AML or ALL and the
effects of Ara-C plus thioguanine in 2
adults. Bone-marrow aspirates were
studied at various time intervals after
start of treatment as well as at successive
courses oftherapy. Reproducible changes
were first seen as early as 19 h after
treatment as asymmetric DNA/cell dis-
tributions, and a decrease in the frequency
of cells with G2 DNA content, indicating
retardation of cell cycle traverse in early
S phase (Fig. 2). Repeated administra-
tion of the drug caused the accumulation
in S phase of as much as 70% of the cells
(Patient I.G.). Comparable observations
based on radioautography (Lampkin,
McWilliams and Mauer, 1971a) and pulse
cytophotometry (Buchner et al., 1975)
have been reported. A detailed account
of the effect of Ara-C in human patients
and in model systems will be presented
elsewhere.
L-asparaginase
A young patient (A.C.) in relapse of
ALL was studied during chemotherapy
with L-asparaginase. In the DNA/cell
histographs (Fig. 3), tumour cells appeared
as an actively proliferating population of
aneuploid cells mixed with a smaller
fraction of cells with diploid DNA con-
tent. The latter cells were proliferating
normal bone-marrow cells as evident from
the presence of normal cells in G2 and
M phase (channel 60, Fig. 3). Three
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Pie. 2.--DNA/cell distribution of ALL cells before (curve A) and 24 h after (curve B) therapy with
Ara-C. Note asymmetric (listribution in cuirve B due to arrest in early S phase (channels 40-55).
days after therapy, a drastic drop in S and
G2-phase tumour cells was observed and
the proportion of normal cells had almost
doubled without a detectable reduction in
G2-phase cells. These changes are com-
patible with the cell lysis and the block in
G1 phase specifically induced in tumour
cells by L-asparaginase (Saunders, 1972).
Similar changes will probably be found in
samples taken within less than 3 days.
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FIG. 3.-DNA/cell distribution ofaneuploid ALL cells before (curveA) and 72 hafter (curveB) therapy with L-asparaginase (Table, A.C.). Channel 30 = normal cells in G1; channel 37 = tumour cells in G1; channel 60 = G2 + M-phase normal cells; channel 75 = same of tumour cells.
Alikylating drugs
Two adult patients suffering from
multiple myeloma were studied during
treatment with high doses of Melphalan
(D.B. and M.E.). Patient M.E. showed
a marked accumulation of tumour cells
in the S phase (Fig. 4). A considerable
degree of cell death was indicated by the
appearance of signals in the first channels
of the histograph and by broadening of
the G1 peak. This type of response
could be duplicated by x-irradiation in
systems in vitro and confirms the in-
hibition of DNA synthesis by alkylating
drugs (Lampkin, Nagao and Mauer,
12
1971b). In patient M.E., the initial
number of S-phase cells amounted to
15% indicating a population of actively
proliferating tumour cells. The shaded
area in Fig. 4, superimposed on the dark
histograph of untreated cells at the same
scale, demonstrates that approx. 60-70%
of the cells had been killed or arrested in
S phase after 24 h of treatment. At
least a comparable percentage of cells
must have been in cycle or had been
recruited into cycle during this period.
In spite of the pronounced cytophoto-
metric response, the patient did not
respond to treatment clinically.
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FIG. 4.-DNA/cell distribution of myeloma cells before (dark area) and 24 h after (shaded area)
treatment with Melphalan, (Table, AI.E.). Note accumulation of cell debris (channels 10-25)
and of cells in S phase (channels 50-70). Both hi.stographs are at the same scale.
In the untreated bone-marrow of
patient D.B., S-phase cells were 800.
No changes in the DNA/cell distributions
were observed after 24 or 48 h of treat-
ment.
Accumulation in late S phase and in
G2 phase was also observed in a patient
(P.S.) subjected to therapy with nitrogen
mustard, vincristine, procarbazine and
prednisone (MOPP) for 24 h.
Adriamycin
Adriamycin administered alone or
combined with vincristine caused a re-
duction in the percentage of S-phase cells
and accumulation of cells with G2 DNA
content. This response to adriamycin
has been described already by others
(Tobey, 1972; Strijckmansetal., 1973). In
patient Y.B., the proportion of S-phase
cells dropped from 300o to 8% and that
of cells in G2 increased from 90% to 15%
in 24 h. In patient T.I., S-phase cells
were reduced from 6% to 3% and (4
phase cells had increased from 200 to
10% in the same period. After 48 h the
corresponding figures for patient H.P.
were from 22% to 8% and from 2% to
110% for S and G2-phase cells respectively.
Patient M.A. responded to adriamycin
in the first cycle of treatment by a four-
fold reduction in S-phase cells. However,
in the second cycle no cytophotometric
nor clinical response to adriamycin
followed by vincristine was noted. Simi-
larly patient T.E., who failed to respond
to chemotherapy, did not show significant
changes in the DNA/cell distributions.
Pulse cytophotometric changes and clinical
effects
In the Table early drug effects on the
DNA/cell histographs are compared with
the observations made clinically. The
Table includes 19 patients (except for
VUIW rw.
%--- . %amPULSE CYTOPHOTOMETRY AIDS CHEMOTHERAPY
one technical failure) from whom samples
were studied before and at least 24 h
after the start of treatment. With one
exception all patients who showed early
changes in the histographs also responded
clinically to the therapy, the responses
ranging from a decreased tumour cell
frequency in smears from bone-marrow or
peripheral blood to " complete re-
missions ". Ingeneral, responses to treat-
ment could be inferred from the pulse
cytophotometric assay much earlier (i.e.
Patient A.C.) than from clinical observa-
tions, except for ALL patients treated
with prednisone and vincristine.
In 5 patients (Patients nos. 6, 9-3, 14,
15-2 and 18) the absence of characteristic
changes in the DNA/cell distribution was
associated with clinical unresponsiveness.
One patient (M.E.), although showing a
pronounced reaction in the cytophoto-
metric assay (cf. Fig. 4), did not respond
clinically to the treatment.
DISCUSSION
The aim of the present studies was to
investigate whether the effect of chemo-
therapy would be timely and characteristi-
cally reflected by perturbations in the
DNA/cell distributions obtained by pulse
cytophotometry. Secondly, drug-induced
changes were compared with the clinical
evaluation of drug effectiveness.
In most samples investigated at 24 h
or more following the start of therapy,
characteristic changeswereobservedwhich
could be related to the known mode of
action of the drugs. The results are in
good agreement with those of comparable
studies based on radioautographic or
pulse cytophotometric techniques.
Exceptions are the absence of a G2
accumulation after vincristine in child-
hood leukaemia, in contrast to the findings
in adult leukaemia (cf. Hillen et al., 1975)
and in normal bone-marrow. Secondly,
although accumulation of cells with S-
TABLE-Correlation between Pulse Cytophotometric and Clinical Responses to
Chemotherapy
Diagnosis and
1st aspirate
(h after
Cytophoto-
metric (Clini
Patient stage Therapy therapy) response respo
1 V.K. (a) ALL (rel). Predn., vcr 24 + +
2 S.E. (a) ALL (rel.) Predn., vcr 24 + +
3 B.V. (a) ALL (rel.) Predn., vcr 24 + +
4 R.C. (c) LS (l.tr.) Predn., vcr 24 + +
5 P.W. (c) LS (l.tr.) Predn., ver 24 + +
6 B.V. (c) MoL (rel.) Predn., vcr 24
7 V.M. (a) AML (rel.) Ara-C 24 + +
8 V.P. (c) AML (rel.) Ara-C 24 + +
9-1 I.G. (c) ALL (rel.) Ara-C 24 + +
9-2 I.G. (c) ALL (rel.) Ara-C 19 + +
9-3 I.G. (c) ALL (rel.) Ara-C 48
10 F.O. (a) AML (rel.) Ara-C, thioG. 24 + +
11-1 P.S. (a) EL (prim.) Ara-C, thioG. 38 + +
11-2 P.S. (a) EL (rel.) Adriam., vcr 48 + +
12 Y.B. (c) NB (inf.) Adriam. 24 + +
13 T.I. (a) AML (rel.) Adriam., vcr 24 + +
14 T.E. (c) ALL (rel.) Adriam., vcr 24 -_
15-1 M.A. (a) AML (rel.) Adriam. 24 + +
15-2 M.A. (a) AML (rel.) Adriam., vcr 48
16 A.C. (c) ALL (rel.) L-asparaginase 72 + +
17 P.S. (c) LS (l.tr.) MOPP 24 + +
is D.B. (a) MM Melphalan 24
19 M.E. (a) MMr Melphalan 24 +
Abbroviations:
(a)
= adult patient; (c)
= child. ALL = acutelymphocytic leukaemia; LS = lymphosarcoma;
NB = neuroblastoma; MoL = monocytic leukaemia; AML = acute myelocytic leukaemia;EL =
erythroleukaemia; AIM
= multiplemyeloma. (rel.)
= relapse; (l.tr.) = leukaemic transformed; (prim.)
primary disease; (inf.)
= bone-marrow infiltration. Predn. = prodnisone; ver = vincristine: Ara-C
cytosine arabinoside; thioG = thioguanine; Adriam. = adriamycin.
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phase content during therapy with Ara-C
has been observed by others as well
(Lampkin et al., 1971b; Buchner et al.,
1975) it has not been found by IHillen
et al. (1975). This discrepancy may be
explained by differences in the prepara-
tive techniques, particularly the pre-
treatment with pepsin, which eliminates
damaged cells (Berkhan, 1972). Since
the pepsin treatment usedinthisstudy was
relatively mild and was not even included
in the preparations of Buchner et al.
(1975), cells arrested in S phase may have
been selectively removed fromtheprepara-
tions studied by Hillen et al.
The selective removal of dead cells by
pepsin is not in conflict with our observa-
tions of dead cells after x-rays or
alkylating agents (Fig. 4). These agents
are known to kill cells with delayed cell
lysis, a property used to prepare feeding
layers of irradiated cells and to inactivate
cells with mitomycin for mixed lympho-
cyte cultures.
The effect of most drugs in first case
leukaemia is well documented and can be
monitored over time by routine methods,
for instance in the case of ALL. There-
fore a correlation between pulse cyto-
photometric changes and clinical response
in primary ALL is largely confirmative
and of little practical value. However,
this may not hold in all cases, for example
in the use of L-asparaginase, or in cases
of relapse when a clinical response is less
likely to occur. The early suggestion by
pulse cytophotometry ofdrug insensitivity
in 5 patients indicates that it is basically
possible to develop drug sensitivity tests
using this technique.
In fact the pulse cytophotometric
assay meets a number of conditions which
a successful predictive test would have
to fulfil. The assay is simple and rapid and
does not cause unacceptable discomfort
to most ofthe patients. Moreover, unlike
in vitro cytotoxicity tests, the assay is
maximally representative for factors in
situ which affect local concentrations of
active drug metabolites and cytokinetic
reactions.
It is not overlooked that these studies
had to be limited to patients whose bone-
marrow contained mainly leukaemic
blasts. Pulse cytophotometric studies are
invalid for mixed populations of normal
and tumour cells, except in the case of
tumour cell aneuploidy (cf. Fig. 3).
However, cell separation techniques are
in rapid evolution and concentration of
proliferating tumour blasts from complex
populations has been successfully achieved
by density gradient separation techniques
(Cleton et al., 1975).
While admittedly preliminary, the
results suggest that the pulse cytophoto-
metric assay may contribute to the
design of an optimal chemotherapeutic
strategy, particularly in cases of relapse
from acute leukaemia and in childhood
lymphoma.
The supply of some samples by Dr
K. Roosendaal, Wilhelmina Hospital,
University of Amsterdam and by Drs H.
Behrend and A. Voute and collaborators,
The Emma Children's Hospital, Amnster-
dam, is gratefully acknowledged.
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